Business
Inditex’s Fall to €22.22 Brings its Dividend Yield to 5%
Specifically, Inditex, which has an Ebitda for 2022 of €8.02 million, according to FactSet data, expects a 4.5% growth in its gross operating profit for 2023, when it would touch €8.37 million, and 4.7% for 2024, when an Ebitda of €8.75 million is forecast for the company. Colonial closes this list, with a dividend of 4.02% for 2022 and Ebitda growth of 13.5% for 2023 and 9.6% for 2024.
Despite the fact that after the arrival of the new Inditex management team of Marta Ortega and Óscar García Maceiras in April, the company has risen by 18%, in the year as a whole the red continues to be its terrain. An environment that, on the other side of the coin, gives rise to the most attractive returns. The textile company is one of the few Ibex companies, along with Iberdrola, Colonial, and Sacyr, which, in addition to presenting growth in its gross operating profit (Ebitda) for the next two years, offers returns, at current prices, of 4.7%. A payment that would rise to 5% in the event that the company falls from the current share price of €23.14 to the four ducklings: €22.22, after dropping more than 9% in the last week.
Last March, when it had already lost more than 29%, Inditex announced that in 2022 it would pay a dividend of €0.93 per share, which represents an increase of 33% over the previous year and a payout of almost €2.9 million. A statement hinted that, with the new management at the helm of the company, the group would continue to maintain its remuneration policy.
Now, with a stock market fall of more than 18% in 2022, despite the rebound of more than 8% experienced in the first two weeks of August, when it reached levels of January 2022, the payment offered by the company is close to around 5%, that is, it is among the most attractive of the main Spanish selective. In addition, Inditex is the firm with the highest remuneration for 2022 among the companies that expect growth in their gross operating profit for 2023 and 2024.
Specifically, Inditex, which has an EBITDA for 2022 of €8.02 million, according to FactSet data, expects a 4.5% growth in its gross operating profit for 2023, when it would touch €8.37 million, and 4.7% for 2024, when an Ebitda of €8.75 million is forecast for the company.
Read more about Inditex and find the latest business news of the day with the Born2Invest mobile app.
Good credentials
Marta Ortega took the helm of Inditex on April 1st with credentials that are hard to beat: almost 6,500 stores around the world, record profits, and her commitment to maintaining the business model, thus closing the stage of Pablo Isla, who left the presidency after 17 years at the company. Thus, the daughter of the founder of the textile empire, Amancio Ortega, and Óscar García Maceiras, CEO of the company, have only needed one semester at the helm of Inditex to gain credibility in their management.
That was demonstrated after the company’s second-quarter results, which reflected strong growth, since, although the profit was lower than expected, the analysts’ consensus had forecast more than 800 million due to the provision made, it was above forecasts.
As a result, the expert consensus, as reported by Bloomberg, currently predicts a 21.7% rise for the textile company, to reach its target price of €28.3.
Those ‘chasing’ Inditex
In the same vein, Sacyr, which has just completed two months since its return to the Ibex 35, is the next company with growth in its Ebitda for the next two years of 10.1% for 2023 and 6.3% for 2024 with higher returns on its payment of 4.6% for 2022.
Iberdrola is third, with a gross operating profit for 2022 of €12.45 million and an Ebitda for 2023 of €13.51 million, i.e. 8.6% more. The company, which recorded a very good performance during the year, especially in its business in the United States and Brazil, informed its shareholders last month that they will receive an extra dividend of €0.005 per share or €1 for every 200 shares for having completed an attendance of more than 70% at the shareholders’ meeting.
Colonial closes this list, with a dividend of 4.02% for 2022 and Ebitda growth of 13.5% for 2023 and 9.6% for 2024.
__
(Featured image by Engin Akyurt via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in elEconomista.es, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
-
Biotech2 weeks ago
Quirónsalud and Roche Farma Sign an Agreement to Promote Healthcare Innovation and Research
-
Business5 days ago
TopRanked.io Weekly Affiliate Digest: What’s Hot in Affiliate Marketing [1xBet Partner Program Review]
-
Biotech1 week ago
Novo Nordisk: Ozempic Gets Positive Evaluation for Kidney Treatment
-
Crypto7 days ago
Blackrock Just Launched the RWA Tokenization Snowball. Here’s How to Profit With SurancePlus [NASDAQ: OXBR]